Vasopressin

News Vasopressin

• Vantia Therapeutics reveals structure of its novel small molecule treatment for dysmenorrhoea, VA111913

  Vantia Therapeutics announced that it revealed the structure of drug candidate VA111913 for the first time at the American Chemical Society’s (ACS) National Meeting in San Francisco, USA. The structure was presented as part of an oral session at the meeting and also chosen by ACS to be highlighted i more

• Vantia Therapeutics’ lead candidate VA106483 enters Phase IIb trial for nocturia

  Vantia Therapeutics announced it has begun its planned Phase IIb trial of its lead development compound VA106483 for nocturia. The study is a randomised, double-blind, placebo-controlled study and is expected to recruit approximately 120 male patients at 20 centres in the US. The study will primaril more

• European Commission approves Samsca for Hyponatraemia

  Otsuka Pharmaceutical Co., Ltd. and Otsuka Pharmaceutical Europe Ltd. (OPEL) announced that the European Commission has approved the Marketing Authorisation Application for the company’s oral once-daily medication Samsca™(tolvaptan), a selective V2-vasopressin receptor antagonist, for the treatment more

Publications Vasopressin

• Stability and dynamics of forebrain V1aR and OTR during pregnancy in prairie voles

  Abstract During pregnancy, females undergo several physiologically driven changes that facilitate adaptive behaviours and prepare the mother to care for her developing offspring. The nonapeptide hormone oxytocin is best recognised for its involvement in mammalian pregnancy and has been tightly a more

• Oxytocin in Brattleboro rats: Increased synthesis is contrasted by blunted intrahypothalamic release from supraoptic nucleus neurons

  Abstract Adult male Brattleboro rats were used to investigate the impact of the congenital absence of vasopressin on the release pattern of oxytocin within the hypothalamic supraoptic nucleus (SON) in response to a 10‐min forced swimming session and osmotic stimulation. Both immunohistochemical more

• Intranasal application of vasopressin fails to elicit changes in brain immediate early gene expression, neural activity and behavioral performance of rats

  Abstract Intranasal administration has been widely used to investigate effects of the neuropeptides vasopressin and oxytocin on human behaviors and neurological disorders, but exactly what happens when these neuropeptides are administered intranasally is far from clear. In particular, it is not more

Market studies Vasopressin

• Anxiety Disorders Therapeutics - Pipeline Assessment and Market Forecasts to 2017

  Introduction GlobalData, the industry analysis specialist, has released its new report, “Anxiety Disorders Therapeutics - Pipeline Assessment and Market Forecasts to 2017”. The report is an essential source of information and analysis on the global anxiety disorders market. The report identifies th more

Websites Vasopressin